US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

4.13

+0.01000.24%

Post-market: 4.130.00000.00%19:22 EDT

Volume:14.41K

Turnover:58.59K

Market Cap:3.65M

PE:-0.06

High:4.15

Open:4.06

Low:4.02

Close:4.12

52wk High:53.20

52wk Low:3.91

Shares:884.70K

Float Shares:811.00K

Volume Ratio:0.35

T/O Rate:1.78%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-67.3644

EPS(LYR):-94.0505

ROE:-1235.06%

ROA:-71.33%

PB:-1.06

PE(LYR):-0.04

Loading ...

Overview Company News Filings

Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts

Super League Enterprise Inc expected to post a loss of 26 cents a share - Earnings Preview

Press Release: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Super League Enterprise, Inc. (NASDAQ:SLE) Not Doing Enough For Some Investors As Its Shares Slump 33%

Simply Wall St.

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

EXCLUSIVE: AVID And Super League Bring Learning To Roblox, Helping Teens Build Real-World Skills Through Gaming

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

This Super League Enterprise Insider Increased Their Holding By 46% Last Year

Simply Wall St.

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Royalty Pharma Announces R&D Funding Collaboration With Biogen

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":4.13,"timestamp":1754683200000,"preClose":4.12,"halted":0,"volume":14405,"hourTrading":{"tag":"盘后","latestPrice":4.13,"preClose":4.13,"latestTime":"19:22 EDT","volume":68,"amount":276.72,"timestamp":1754695370968},"delay":0,"floatShares":811000,"shares":884699,"eps":-67.3644,"marketStatus":"Market Closed","change":0.01,"latestTime":"08-08 16:00:00 EDT","open":4.06,"high":4.1499,"low":4.0201,"amount":58585.98489500001,"amplitude":0.031505,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-67.3644,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754899200000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":4.12,"preHourTrading":{"tag":"盘前","latestPrice":4.11,"preClose":4.12,"latestTime":"09:29 EDT","volume":25,"amount":102.5501,"timestamp":1754659773373},"postHourTrading":{"tag":"盘后","latestPrice":4.13,"preClose":4.13,"latestTime":"19:22 EDT","volume":68,"amount":276.72,"timestamp":1754695370968},"volumeRatio":0.34527215263105515},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":811000,"roa":"-71.33%","roe":"-1235.06%","lyrEps":-94.05048,"volumeRatio":0.34527215263105515,"shares":884699,"dividePrice":0,"high":4.1499,"amplitude":0.031505,"preClose":4.12,"low":4.0201,"week52Low":3.91,"pbRate":"-1.06","psRate":"0.25","week52High":53.2,"institutionHeld":0,"latestPrice":4.13,"eps":-67.3644,"divideRate":0,"volume":14405,"delay":0,"ttmEps":-67.3644,"open":4.06,"prevYearClose":24.7,"prevWeekClose":4.15,"prevMonthClose":4.3,"prevQuarterClose":4.635,"fiveDayClose":4.15,"twentyDayClose":5.82,"sixtyDayClose":6,"earningDate":1755100800000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"date":"2025-08-14","symbol":"SLE","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":-6.8,"defaultRemindTime":1755201600000,"name":null,"time":"Post Market","dateTimestamp":1755144000000,"actualEps":null},{"market":"US","date":"2025-06-23","symbol":"SLE","defaultRemindTime":1750685400000,"type":"split","dateTimestamp":1750651200000,"forFactor":40,"toFactor":1,"ratio":40},{"market":"US","date":"2025-05-15","symbol":"SLE","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-08-08","current":-0.233576,"percent":0.679912,"low":-0.555206,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"high":-0.044016,"avg":-0.271463,"sd":0.100436,"marketCap":3644959},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959}],"updateTime":1754759451458},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521205319","title":"Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521205319","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521205319?lang=en_us&edition=fundamental","pubTime":"2025-03-23 20:43","pubTimestamp":1742733837,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc.  stands against other penny stocks with the biggest upside potential.Further insights came from Chris Retzler, portfolio manager for Needham’s Small Cap Growth Fund, who shared his outlook for small-caps on CNBC’sSquawk Boxon January 17, 2025. He noted that small-cap companies are looking for policy certainty, and once the new administration’s direction becomes clearer, we could see growth accelerate. Globally, the EV sector is thriving, even as it faces some hurdles in the United States.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-acet-among-penny-124357821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","NQmain","USAW.SI","USJW.SI","MNQmain","TSYW.SI","ACET","BK4077","BK4139","NVIW.SI","SQQQ",".IXIC","QID","SLE","PSQ","TQQQ"],"gpt_icon":1},{"id":"2521402902","title":"Super League Enterprise Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521402902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521402902?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:13","pubTimestamp":1742555586,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc  expected to post a loss of26cents a share - Earnings Preview Super League Enterprise Inc SLE.OQ SLE.O is expected to show a fall in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2520437679","title":"Press Release: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520437679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520437679?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"on track with 33 authorized treatment centers as of March 19, 2025,-- Obe-cel MHRA and EMA marketing authorizations expected in H2 2025. -- Initial six patients dosed in Phase 1 dose confirmation trial in Systemic. -- Company to provide clinical development program updates, including plans. for expansion in autoimmune diseases, at R&D investor event to be held on. call participants should pre-register using the link at the bottom of. \"As we begin 2025, we have two key objectives: execute on the commercial launch of AUCATZYL in adult ALL both in the U.S. and entering new markets; and establish the next wave of investments to expand the obe-cel opportunity, advance our clinical pipeline and drive future growth. We look forward to discussing our plans to continue to expand our clinical pipeline and strategy at our R&D event in April.\".  for the treatment of adult patients with relapsed or","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","EBMT","BK4077","LU2355687059.USD","NICE","LENZ","BK4107","BK4139","SLE","ASH","BK4218","LU1571399168.USD","LU1699723380.USD","LU0985320562.USD","ALL","BK4533","BK4585","BK4023","BK4543","BK4109","BK4022","BK4181","AUTL","SOHO","BK4588","LU2463526074.USD","BK4232","R","BK4566","IE00BFMHRM44.USD"],"gpt_icon":0},{"id":"2520933601","title":"Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520933601","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520933601?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:05","pubTimestamp":1742414700,"startTime":"0","endTime":"0","summary":"– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated;","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/19/3045800/0/en/Alumis-Reports-Year-End-2024-Financial-Results-and-Highlights-Recent-Achievements.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1732800096.USD","LU2089284900.SGD","LU0106831901.USD","LU0795875169.SGD","LU1720051108.HKD","LU2089283258.USD","LU2111349929.HKD","LU1162221912.USD","LU1732799900.SGD","LU1363072403.SGD","LU0158827948.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4007","LU0267386448.USD","LU0912757837.SGD","LU0106261372.USD","LU2028103732.USD","LU1668664300.SGD","ALMS","CNS","LU0225283273.USD","LU2023251221.USD","LU0158827781.USD","BK4581","LU1989772923.USD","BK4077","LU1989772840.SGD","LU2357305700.SGD","LU1720051017.SGD","LU0971096721.USD","LU2347655156.SGD","BK4534","BK4127","LU0006306889.USD","LU2271345857.HKD","SLE","LU0320765646.SGD","BK4504","LU0098860793.USD","LU1074936037.SGD","LU1548497426.USD","BK4516","BK4585","LU2133065610.SGD","LU0314104364.USD","BK4135","LU0795875086.SGD"],"gpt_icon":0},{"id":"2520181351","title":"Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520181351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520181351?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth.At its research and development facility at Cambridge Science Park, Conduit is enhancing its IP portfolio and optimize the formulation of its pipeline assets. In the laboratory, the Company is evaluating the assets licensed through the AstraZeneca partnership and other assets of critical interest. Significant progress has also been made in securing intellectual property  protection for Conduit’s lead asset, AZD1656. Recent milestones include the grant of a composition-of-matter patent for the AZD1656 Cocrystals by the Japan Patent Office  and IP Australia, with pending applications at the USPTO and European Patent Office, and other global patent offices, expected to be approved early in the second quarter. In addition, Conduit is actively worki","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-provides-research-development-123000754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IP","LU1481599808.USD","LU2065732104.USD","BK4136","BK4121","CDTTW","LU1487256676.USD","PRGS","SLE","BK4097","BK4077","LU2463526074.USD","LU1481600234.SGD","BK4585","BK4588","CDT"],"gpt_icon":0},{"id":"2518705315","title":"Super League Enterprise, Inc. (NASDAQ:SLE) Not Doing Enough For Some Investors As Its Shares Slump 33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518705315","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518705315?lang=en_us&edition=fundamental","pubTime":"2025-03-12 02:50","pubTimestamp":1741719043,"startTime":"0","endTime":"0","summary":"Super League Enterprise, Inc. ( NASDAQ:SLE ) shareholders that were waiting for something to happen have been dealt a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4300003-choice1-main-header/1585186588101","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4300003-choice1-main-header/1585186588101"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/media/nasdaq-sle/super-league-enterprise/news/super-league-enterprise-inc-nasdaqsle-not-doing-enough-for-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQQ","MNQmain","LU2210150020.SGD","PSQ","SLE","QID","NDAQ",".IXIC","BK4077","IE00B64PRP62.GBP","ISBC","SQQQ","USJW.SI","IE00BKPKM429.USD","NQmain","BK4211","BK4112","IE00B3QW5Z07.USD","BK4588","QLD","LU2095319765.USD","IE00BGHQF748.EUR","USAW.SI","BK4585","LU2210149790.SGD","TSYW.SI","NVIW.SI"],"gpt_icon":1},{"id":"2518482877","title":"Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2518482877","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518482877?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD. CARLSBAD, Calif., March 11, 2025  -- Exagen Inc. ,a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.Achieved key commercial milestone with completion of 1,000,000th patient tested by AVISE CTD. Featured five abstracts at the 2024 American College of Rheumatology  annual meeting highlighting Exagen’s innovative research on novel T Cell biomarkers for Lupus and sero-negative autoantibodies for rheumatoid arthritis, in addition to a plenary presentation in collaboration with Johns Hopkins University, highlighting a urinary biomarker panel that holds the potential to guide precision management of Lupus Nephritis patients. Secured New York State Department of Health ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exagen-inc-reports-strong-fourth-120000907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XGN","BK4139","SLE","ACR","BK4077","RA","BK4110"],"gpt_icon":0},{"id":"2518748426","title":"EXCLUSIVE: AVID And Super League Bring Learning To Roblox, Helping Teens Build Real-World Skills Through Gaming","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748426","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518748426?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:45","pubTimestamp":1741693527,"startTime":"0","endTime":"0","summary":"On Tuesday, AVID  and Super League Enterprise Inc  announced the launch of AVID Creator Planet, an educational adventure on Roblox Corp  for students ages 13+ to learn valuable executive function and durable skills in and out of the classroom.Funded by a grant from the Roblox Community Fund, AVID Creator Planet focuses on practicing durable skills such as problem-solving, critical thinking, collaboration, and communication.Each phase, from planning and construction to adaptation and evaluation, challenges learners to apply these principles in dynamic and interactive scenarios.To bring the AVID Creator Planet learning experience into the classroom, AVID has created a full suite of free resources around the game in AVID Open Access, including step-by-step lessons and all the resources necessary for teachers and students.Set on Equinova, an extraterrestrial planet, Roblox users learn durable skills and practice engineering design through building challenges that use a variety of materials","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-avid-super-league-bring-114527916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4565","LU0348723411.USD","AVID","BK4551","BK4554","BK4170","BK4547","LU1861558580.USD","BK4535","BK4077","BK4085","LU1861559042.SGD","BK4585","BK4588","SLE","RBLX","BGSX"],"gpt_icon":0},{"id":"2517911392","title":"Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911392","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911392?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":"Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis  patient cohort in 1H25. Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25. Initiation of ADI-001 Phase 1 clinical trial patient enrollment in systemic lupus erythematosus , systemic sclerosis , idiopathic inflammatory myopathy  and stiff person syndrome  expected in 2Q25; anti-neutrophil cytoplasmic autoantibody  associated vasculitis  patient enrollment expected to be initiated in 2H25. Continuing to advance phase 1 trial of ADI-001 in autoimmune diseases. In November 2024, Adicet announced the dosing of the first patient in the Phase 1 trial evaluating ADI-001 in LN. Enrollment for SLE, SSc, IIM, and SPS patients is expected to commence in the second quarter of 2025, with the initiation of AAV patient enrollment anti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-reports-fourth-quarter-210100654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4022","ACR","LU2065732104.USD","BK4097","BK4110","BK4077","BK4080","BK4230","CAR","ACET","BK4139","PRGS","IIM","SITC","SLE"],"gpt_icon":0},{"id":"2517792973","title":"Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517792973","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517792973?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:01","pubTimestamp":1741208460,"startTime":"0","endTime":"0","summary":"Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE. Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T-cell Dose Expansion in Additional B Cell-mediated Autoimmune Diseases. First FT819 Off-the-Shelf CAR T-cell Patient Treated without Conditioning Chemotherapy as Add-on to Maintenance Therapy in SLE. Phase 1 Dose Expansion Initiated for SLE using Flu-free Conditioning Regimen. Based on clinical data from the first three patients treated with FT819 in its ongoing multi-center, Phase 1 clinical trial for moderate-to-severe systemic lupus erythematosus  , the Company has initiated dose expansion in up to 10 patients at 360 million cells. The dose expansion stage is designed to evaluate the safety and efficacy of a fludarabine -free conditioning regimen, consisting of either bendamustine alone or cyclophosphamide alone, followed by a single dose of FT819. The Company is also a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-reports-fourth-quarter-210100391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SITC","LU2463526074.USD","BK4230","IE00B66KJ199.SGD","BK4109","BK4022","BK4080","FATE","ASH","IE00B7SZL793.SGD","BK4077","CAR","LU2065731478.USD","BK4231","IIM","BK4112","IE0031619046.USD","IE00B19Z4B17.USD","BK4006","CRS","SLE","TRAC"],"gpt_icon":0},{"id":"2514350959","title":"Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris","url":"https://stock-news.laohu8.com/highlight/detail?id=2514350959","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514350959?lang=en_us&edition=fundamental","pubTime":"2025-02-28 08:05","pubTimestamp":1740701100,"startTime":"0","endTime":"0","summary":"Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple autoimmune diseases. Viatris previously acquired rights to cenerimod in all other territories from Idorsia, and now has exclusive global rights. Nxera will receive an upfront payment of US$10 million from Viatris, and is eligible to receive a further milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales in the assigned territories. Viatris will be the exclusive owner of cenerimod rights in Japan and APAC . Viatris gained exclusive rights to cenerimod in all other territories from Idorsia through a research and development agreement signed in February 2024 and following this agreement with Nxera, now owns exclusive global rights to the candidate.About ViatrisViatris Inc. is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically add","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nxera-pharma-assigns-japan-apac-000500896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4528","LU2087621335.USD","BK4205","SLE","LU1839511570.USD","SOLTF","BK4077","UK","VTRS","BK4583","BK4007","BK4588","BK4233","BK4585"],"gpt_icon":0},{"id":"2514806912","title":"Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514806912","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514806912?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, February 27, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration  has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with systemic sclerosis .Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.This press release contains \"forward-looking statements\" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"would\" and similar expressions are intended to identify forward-looking statements, althoug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-receives-fda-fast-120000634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1803068979.SGD","LU1074936037.SGD","BK4077","SLE","LU1861219969.SGD","BK4512","LU1670711040.USD","LU0124384867.USD","LU2272731600.USD","BK4561","LU2458330169.SGD","LU2458330243.SGD","FAST","LU0444971666.USD","LU1978683503.SGD","LU2237443382.USD","BK4139","BK4141","IE00BD6J9T35.USD","LU1670710661.SGD","LU0109392836.USD","IE00BZ199S13.USD","LU0314104364.USD","CAR","BK4230","IE00B5949003.HKD","IE0009356076.USD","LU2237443549.SGD","LU0082616367.USD","BK4605","ADI","LU1244550221.USD","LU1992135399.USD","ACET","LU2272731782.SGD","LU1815336760.USD","LU1992135472.HKD","LU1244550494.USD","BK4515","LU0719512351.SGD","LU1670710588.SGD","LU0724618433.USD","LU2237443978.SGD","LU2298322129.HKD","LU2237443622.USD","LU1861214812.USD","LU1244550577.SGD","LU1642822529.SGD","LU2237438978.USD","LU0889565833.HKD"],"gpt_icon":0},{"id":"2514180530","title":"Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514180530?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus  expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S.Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions. Cash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028. CAMBRIDGE, Mass., Feb. 27, 2025  -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2024.CLN-978 : Systemic lupus erythematosus and rheumatoid arthritis. The global Phase 1 study in moderate to severe SLE is ongoing with site expansion in the United States, Europe and Australia, and the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-provides-corporate-reports-120000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RA","SLE","CGEM","BK4139","BK4077"],"gpt_icon":0},{"id":"2514054798","title":"On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2514054798","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514054798?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Revenue in 2024 increased to  6.15 billion, a plus of 17% ,Net sales were up by 15% to 5.61 billion  driven by a strong, triple- and double-digit growth performance of newly launched growth drivers: BIMZELX, EVENITY, FINTEPLA, RYSTIGGO and ZILBRYSQ as well as solid contribution from CIMZIA and BRIVIACT reaching its peak sales two years ahead of target. Underlying profitability  went up to  1.48 billion, a plus of 9% ,24.0%of revenue; Core EPS3 increased to  4.98. R&D update: Doxecitine and doxribtimine in thymidine Kinase 2 deficiency filed in U.S. – with granted priority review - and in EU; 1st phase 3 with positive results for dapirolizumab pegol in systemic lupus erythematosus , 2nd phase 3 started; Phase 2a study in atopic dermatitis with UCB9741/galvokimig showed positive and convincing data. Sustainability with significant improvement in patient access, CO2 reduction and ESG ratings. Financial guidance for 2025: Revenue expected to grow to  6.5-6.7 billion, adjusted EBITDA2 to re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/growth-path-decade-plus-strong-120000933.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/growth-path-decade-plus-strong-120000933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CET","PSO","BK4077","AS","BK4111","SLE","BK4204","UCBJF","BK4202","UCBJY"],"gpt_icon":0},{"id":"2512443527","title":"This Super League Enterprise Insider Increased Their Holding By 46% Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2512443527","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512443527?lang=en_us&edition=fundamental","pubTime":"2025-02-20 19:01","pubTimestamp":1740049268,"startTime":"0","endTime":"0","summary":"Looking at Super League Enterprise, Inc.'s  insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.Check out our latest analysis for Super League Enterprise. Super League Enterprise Insider Transactions Over The Last Year. The fact that there have been no Super League Enterprise insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in Super League Enterprise and we see no evidence to suggest they are worried about the future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-insider-increased-110108845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2511454270","title":"Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2511454270","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511454270?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:00","pubTimestamp":1739451600,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study paramet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/13/3025817/0/en/Conduit-Pharmaceuticals-Partners-with-Charles-River-in-Clinically-Relevant-Systemic-Lupus-Erythematosus-Model.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2511580714","title":"Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511580714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511580714?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:01","pubTimestamp":1739394060,"startTime":"0","endTime":"0","summary":"Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein. Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028. Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need. Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET. Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – GalapagosNV , a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial results for the full year 2024 and provided an update on the fourth quarter 2024 and its year-to-date performance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galapagos-reports-full-2024-results-210100294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0757428866.USD","BK4023","DM","BK4077","GLPG","BK4588","BK4161","BL","BK4139","ORR","BK4585","BK4094","SLE","FL","BK4546","LU1815336091.USD"],"gpt_icon":0},{"id":"2510878320","title":"Royalty Pharma Announces R&D Funding Collaboration With Biogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2510878320","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510878320?lang=en_us&edition=fundamental","pubTime":"2025-02-12 19:30","pubTimestamp":1739359800,"startTime":"0","endTime":"0","summary":"Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb.  12, 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/12/3024862/0/en/Royalty-Pharma-Announces-R-D-Funding-Collaboration-With-Biogen.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","SLE","LU0456855351.SGD","BK4007","IE00B19Z3581.USD","BK4533","BK4568","IE00B894F039.SGD","LU1894683264.USD","IE00B19Z3B42.SGD","LU0122379950.USD","LU1883839398.USD","SG9999002224.SGD","LU0289739699.SGD","IE00BBT3K403.USD","LU0320765992.SGD","LU0985481810.HKD","LU0058720904.USD","BK4532","BK4585","LU0225771236.USD","LU0306807586.USD","SG9999013999.USD","SG9999003800.SGD","BK4592","LU0234572021.USD","LU0321505868.SGD","IE00BLSP4452.SGD","LU1057294990.SGD","BK4581","IE000M9KFDE8.USD","SG9999011175.SGD","LU1023059063.AUD","PFE","BK4588","BK4139","IE00B19Z9Z06.USD","SG9999001176.USD","BIIB","SGXZ57979304.SGD","LU0889565916.HKD","BK4550","BK4077","LU0321505439.SGD","LU1066051498.USD","IE00B19Z9P08.USD","BK4599","BK4534","LU0306806265.USD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2510575493","title":"CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2510575493","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510575493?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:01","pubTimestamp":1739307660,"startTime":"0","endTime":"0","summary":"-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY continues to gain momentum; new cell patient collection initiations expected to signific","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024578/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","BK4157","AGT","IE00B19Z3B42.SGD","BK4533","LU0061475181.USD","SLE","LU1559883803.SGD","LU2456880835.USD","KSA","UAE","LU0109394709.USD","LU1861559042.SGD","CAR","BK4022","LU2236285917.USD","BK4585","LENZ","CRSP","LU0079474960.USD","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","LU2462157665.USD","MACE","VRTX","LU2362540622.SGD","LU2362541273.HKD","BK4231","LU0058720904.USD","LU0757428866.USD","LU1585245621.USD","BK4139","LU0417517546.SGD","BK4230","BK4183","LU1093756168.USD","VERX","LU0889565916.HKD","LU1430594728.SGD","LU0823416689.USD","AHP","ADC","LU0289739699.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","LU2324357040.USD","LU0566484027.USD","LU1035775433.USD","IE0002270589.USD","IE00B2B36J28.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":99,"code":"91000000","status":"200"}]}}